A study team based in in Guangdong, China reported a phase 1 clinical trial results on three metastatic colorectal cancer patients received adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells (39). The gene discussed is KLRK1; the disease is metastatic colorectal cancer.